Moderna Q2 net loss $1.4B, EPS -$3.62; revenue $344M (-93% YoY); FY23 sales guidance $6-8B

Moderna, Inc.

2023-Q2 EPS reported -$3.39 revenue$2,206,000,000

Q2 revenue $344M vs $4.7B YoY; product sales $293M, down 94% due to lower COVID vaccine volume.
Net loss $1.4B vs net income $2.2B YoY; diluted EPS -$3.62 vs +$5.24.
Cost of sales $731M includes $464M inventory write-downs, $135M unutilized capacity, $75M purchase commitment losses.
Guides FY23 COVID vaccine sales $6-8B; expects ~$1B of APAs deferred to 2024; cost of sales now $3.5-4B.
RSV vaccine submitted globally for approval; Phase 3 melanoma combo trial with Merck initiated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Moderna, Inc. reported the second quarter of 2023 results: revenue $344 million, net income net loss of $1.4 billion, EPS loss per share of $3.62. Guidance reaffirmed.

Period: the second quarter of 2023
Revenue: $344 million
Net income: net loss of $1.4 billion
EPS: loss per share of $3.62
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the second quarter of 2023 was $344 million, compared to $4.7 billion in the same period in 2022, mainly due to a decrease in sales of the Company’s COVID-19 vaccine.

View on SEC.gov

Browse all earnings releases →

Moderna, Inc. filing history →

Source: SEC EDGAR

accession 0001682852-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.